| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/02/2011 | EP2290055A2 Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications |
| 03/02/2011 | EP2289941A2 Administration of agents for the treatment of inflammation |
| 03/02/2011 | EP2289940A2 Treatment of metastatic disease |
| 03/02/2011 | EP2289935A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289934A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289933A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289932A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289931A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289930A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289929A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289928A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289927A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289926A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289925A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289924A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289923A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289922A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289921A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289920A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289919A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289918A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289917A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289916A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289915A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289914A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289913A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289912A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289911A2 Therapeutic use of a growth factor, NsG33 |
| 03/02/2011 | EP2289910A2 Differential in tumour gene products and use of same |
| 03/02/2011 | EP2289909A1 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| 03/02/2011 | EP2289908A1 Use of DG177 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 03/02/2011 | EP2289905A1 Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2alpha receptor |
| 03/02/2011 | EP2289886A1 Peptoid agonists of nerve growth factor and their use as medicaments |
| 03/02/2011 | EP2289566A1 Medical device comprising a haemostatic agent and haemostatic kit comprising the medical device |
| 03/02/2011 | EP2289564A2 Derivatives of aniline as precursors for F18-labeling |
| 03/02/2011 | EP2289552A1 An immunosuppressive agent plus anti-TCR antibodies for the induction of chimerism in transplantation |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289543A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 03/02/2011 | EP2289542A1 Treatment of neurological or neurodegenerative disorders |
| 03/02/2011 | EP2289541A1 Treatment of neurological or neurodegenerative disorders |
| 03/02/2011 | EP2289540A1 Alpha-1-antitrypsin for use in the treatment of chronic fatigue syndrome |
| 03/02/2011 | EP2289539A1 Zinc-free and low-zinc insulin preparations with improved stability |
| 03/02/2011 | EP2289538A1 Use of liver growth factor (lgf) as a neural tissue regenerator |
| 03/02/2011 | EP2289537A1 PDGF for use in the treatment of central nervous system disorders |
| 03/02/2011 | EP2289536A1 Use of bone morphogenetic proteins for healing and repair of connective tissue attachment |
| 03/02/2011 | EP2289535A2 Compositions and methods for promoting wound healing and tissue regeneration |
| 03/02/2011 | EP2289534A1 Modulation of NKG2D |
| 03/02/2011 | EP2289533A1 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| 03/02/2011 | EP2289532A1 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| 03/02/2011 | EP2289531A2 Medicaments for increasing endogenous erythropoietine (EPO) |
| 03/02/2011 | EP2289525A1 Use of IL-21 for expanding lymphoid cells and for anticancer adoptive immunotherapy |
| 03/02/2011 | EP2289515A2 Combinations comprising a diaryl urea and an interferon |
| 03/02/2011 | EP2289513A2 Method for decreasing the blood glucose level in mammals |
| 03/02/2011 | EP2289498A1 Use of inhibitors of glutaminyl clyclase |
| 03/02/2011 | EP2289490A1 Charged lipoprotein complexes and their uses |
| 03/02/2011 | EP2289352A2 Agent for use in the case of fructose intolerance |
| 03/02/2011 | EP2288624A2 Compositions and methods for inhibiting shiga toxin and shiga-like toxin |
| 03/02/2011 | EP2288621A2 Il-23 receptor antagonists and uses thereof |
| 03/02/2011 | EP2288616A1 Peptidylarginine deiminase (pad) inhibitors |
| 03/02/2011 | EP2288615A1 Selective caspase inhibitors and uses thereof |
| 03/02/2011 | EP2288396A2 Stimulation of cartilage formation using reduced pressure treatment and chondrocytes |
| 03/02/2011 | EP2288387A1 Novel soluble cd83 polypeptides, formulations and methods of use |
| 03/02/2011 | EP2288378A1 Pharmacological targeting of vascular malformations |
| 03/02/2011 | EP2288377A1 Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
| 03/02/2011 | EP2288376A2 Methods of generating and using procollagen |
| 03/02/2011 | EP2288375A1 Pegylated insulin lispro compounds |
| 03/02/2011 | EP2288374A2 Novel n-and c-terminal substituted antagonistic analogs of human gh-rh |
| 03/02/2011 | EP2288373A2 Treating dyspnea associated with acute heart failure with relaxin |
| 03/02/2011 | EP2288372A2 Means for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory t-cells |
| 03/02/2011 | EP2288371A1 Osteogenic composition including growth factor, soluble cation salt, and organic substrate |
| 03/02/2011 | EP2288370A1 Osteogenic composition including a complex growth factor/amphiphilic polymer, a soluble cation salt, and an organic substrate |
| 03/02/2011 | EP2288369A1 Compositions of gnrh related compounds and processes of preparation |
| 03/02/2011 | EP2288368A1 Compositions of peptides and processes of preparation thereof |
| 03/02/2011 | EP2288367A1 Method of preventing premature delivery |
| 03/02/2011 | EP2288366A2 Method of treating chronic heart failure |
| 03/02/2011 | EP2288365A1 Targeted coagulation factors and method of using the same |
| 03/02/2011 | EP1844070B1 Peptides with neuropeptide-2 receptor (y2r) agonist activity |
| 03/02/2011 | EP1833502B1 Pharmaceutical composition for the treatment of invasive pulmonary aspergillosis |
| 03/02/2011 | EP1824969B1 Improved mevalonate kinase |
| 03/02/2011 | EP1686951B1 Combined cosmetic or therapeutic preparation |
| 03/02/2011 | EP1673633B9 Method for detecting feline immunodeficiency virus |
| 03/02/2011 | EP1673385B1 Macrocyclic peptides active against the hepatitis c virus |
| 03/02/2011 | EP1668030B1 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins |
| 03/02/2011 | EP1639004B1 Fluorescein-labelled peptides |
| 03/02/2011 | EP1625159B1 Materials and methods relating to g-protein coupled receptor oligomers |
| 03/02/2011 | EP1513934B1 Genes and polypeptides relating to human colon cancers |
| 03/02/2011 | EP1437969B1 Instruments for autologous transplantation |
| 03/02/2011 | EP1363663B1 Nucleic acid mucosal immunization |
| 03/02/2011 | EP1351992B1 Hybrid peptides for treatment of bacteremia and septicemia |
| 03/02/2011 | EP1261427B1 Microfabricated devices and methods for storage and selective exposure of chemicals |
| 03/02/2011 | EP1185662B1 Dna vaccines for dogs |
| 03/02/2011 | EP1103269B1 Use of HGF for the treatment of ischemic diseases of the extremities |
| 03/02/2011 | EP1100824B1 Compounds with growth hormone releasing properties |
| 03/02/2011 | CN1964732B Peptidic vasopressin receptor agonists |
| 03/02/2011 | CN1927888B Recombination albumen of GLP-1 and analogue thereof and human lysozyme fusion and application thereof |
| 03/02/2011 | CN1889856B Nutritional composition against side effects of chemotherapy of radiotherapy |
| 03/02/2011 | CN1568195B Peptide YY and peptide YY agonists for treatment of metabolic disorders |
| 03/02/2011 | CN101983068A Novel n-and c-terminal substituted antagonistic analogs of gh-rh |
| 03/02/2011 | CN101983067A Treatment of microbial infections |